New tablet attaches to the lining of the GI tract, resists being pulled away
Researchers from MIT and Brigham and Women’s Hospital have designed a new type of pill that, once swallowed, can attach to the lining of the gastrointestinal tract and slowly release its contents. The tablet is engineered so that one side adheres to tissue, while the other repels food and liquids that would otherwise pull it away from the attachment site.
Such extended-release pills could be used to reduce the dosage frequency of some drugs, the researchers say. For example, antibiotics that normally have to be taken two or three times a day could be given just once, making it easier for patients to stick to their dosing schedule.
“This could be adapted to many drugs. Any drug that is dosed frequently could be amenable to this kind of system,” says Giovanni Traverso, a research affiliate at MIT’s Koch Institute for Integrative Cancer Research, a gastroenterologist at Brigham and Women’s Hospital, and one of the senior authors of a paper describing the device in the April 6 issue of the journal Advanced Healthcare Materials.
Robert Langer, the David H. Koch Institute Professor and a member of the Koch Institute, is also a senior author of the paper. The paper’s lead author is Young-Ah Lucy Lee, a technical assistant at the Koch Institute.
Over the past several decades, Langer’s lab has developed many types of materials that can be implanted in the body or attached to the skin for long-term drug release. To achieve similar, long-term drug release in the gastrointestinal tract, the researchers focused on a type of material known as mucoadhesives, which can stick to the mucosal linings of organs such as the stomach.
Scientists have previously explored using this kind of material for drug delivery to the GI tract, but it has proven difficult because food and liquid in the stomach become stuck to the tablet, pulling it away from the tissue before it can deliver its entire drug payload.
“The challenge with mucoadhesives is that the GI tract is a very rough and abrasive environment,” says Lee, a 2014 Wellesley College graduate who began this project as her senior thesis.
To overcome this challenge, the researchers decided to create a dual-sided device, also called a Janus device after the two-faced Roman god. One side sticks to mucosal surfaces, while the other is omniphobic, meaning that it repels everything it encounters.
For the mucoadhesive side, the researchers used a commercially available polymer known as Carbopol, which is often used industrially as a stabilizing or thickening agent. The omniphobic side consists of cellulose acetate that the researchers textured so that its surface would mimic that of a lotus leaf, which has micro and nanoscale protrusions that make it extremely hydrophobic. They then fluorinated and lubricated the surface, making it repel nearly any material.
The researchers used a pill presser to combine the polymers into two-sided tablets, which can be formed in many shape and sizes. Drugs can be either embedded within the cellulose acetate layer or placed between the two layers.
Using intestinal tissue from pigs, the researchers tested three versions of the tablet — a dual-sided mucoadhesive tablet, a dual-sided omniphobic tablet, and the Janus version, with one mucoadhesive side and one omniphobic side.
To simulate the tumultuous environment of the GI tract, the researchers flowed a mix of food including liquids and small pieces of bread and rice along the tissue and then added the tablets. The dual-sided omniphobic tablet took less than 1 second to travel along the tissue, and the dual-sided mucoadhesive stuck to the tissue for only 7 seconds before being pulled off. The Janus version stayed attached for the length of the experiment, about 10 minutes.
Tejal Desai, a professor of bioengineering and therapeutic sciences at the University of California at San Francisco, says this approach could make it possible to deliver larger quantities of drugs through the GI tract.
“The ability to precisely engineer the adhesiveness of a particle opens up possibilities of designing particles to selectively adhere to specific regions of the GI tract, which in turn can increase the local or systemic concentrations of a particular drug,” says Desai, who was not involved in the work.
The researchers now plan to do further tests in animals to help them tune how long the tablets can stay attached, the rate at which drugs are released from the material, and the ability to target the material to specific sections of the GI tract.
In addition to delivering antibiotics, the two-sided material may help to simplify drug regimens for malaria or tuberculosis, among other diseases, Traverso says. The researchers may also further pursue the development of tablets with omniphobic coatings on both sides, which they believe could help patients who have trouble swallowing pills.
“There are certain medications that are known to get stuck, particularly in the esophagus. It causes this massive amount of inflammation because it gets stuck and it causes irritation,” Traverso says. “Texturing the surfaces really opens up a new way of thinking about controlling and tuning how these drug formulations travel.”
The Latest on: Long-term drug release
via Google News
The Latest on: Long-term drug release
- Four-year results from EU RCT validate the long-term safety profile of Philips’ Stellarex low-dose Drug-Coated Balloonon June 26, 2020 at 10:38 am
The global leader in health technology Royal Philips (NYSE: PHG, AEX: PHIA) has announced the four-year results from the ILLUMENATE European Randomized Controlled Trial (EU RCT). New data from the EU ...
- New data reconfirms long-term safety profile of the Philips Stellarex low-dose Drug-Coated Balloonon June 26, 2020 at 1:00 am
ILLUMENATE EU RCT data are the latest from a series of trials evaluating the safety and efficacy of the Philips Stellarex .035" DCB in restoring and maintaining blood flow in the superficial femoral ...
- Advanced & Targeted Drug Delivery Market begins to take bite out of Versioned Long Term Growthon June 25, 2020 at 7:32 am
Latest Study on Industrial Growth of Global Advanced & Targeted Drug Delivery Market 2019-2025. A detailed study accumulated to offer Latest insights about acute features of the Advanced & Targeted ...
- Breakthrough Drug for Covid-19 May Be Risky for Mild Caseson June 24, 2020 at 4:35 pm
That study about dexamethasone has arrived with a big asterisk: While it appears to help severely ill patients, it harms others.
- Indivior's Sublocade shows sustained benefit in long-term observational studyon June 24, 2020 at 11:55 am
Indivior (OTCPK:INVVY +7.9%) announces new data from a 24-month real-world observational study, RECOVER, in people with moderate-to-severe opioid use disorder (OUD) who transitioned from two P ...
- Cassiopea Announces JAAD Publication of Positive Results from A Long-Term Safety Study of Clascoterone Cream 1% for the Treatment of Acneon June 23, 2020 at 5:30 am
PRNewswire/ -- Cassiopea SpA (SIX: SKIN), a specialty pharmaceutical company developing and preparing to commercialize prescription drugs with ...
- Heart surgery leads to long-term opioid use for someon June 22, 2020 at 7:58 am
About one in 10 heart surgery patients who is prescribed an opioid painkiller after the procedure still uses the drugs more than 90 days later, a new study finds.
- ‘A huge opportunity’: Lake County receives federal designation in efforts to reduce drug traffickingon June 20, 2020 at 10:57 pm
Lake County has been awarded a federal designation which will support its efforts to combat drug trafficking. The High Intensity Drug Trafficking Area (HIDTA) program is operated under the White House ...
- AAC Holdings Gains Support From Lenders, Proceeds With Recapitalization Plan to Support Patient Care & Long-Term Growthon June 20, 2020 at 5:00 pm
With Treatment Operations Unaffected, AAC Will Continue Providing High-QualityPatient Care -- CompanyRecapitalizes withInitial$62.5Min IncrementalFinancing& Lower Debt Costto Better Position the ...
- Case study shows heart ailment risk of malaria drug used for COVID-19on June 18, 2020 at 9:46 pm
One of the drugs championed by President Donald Trump as a potential "game changer," led to a potentially deadly heart rhythm disorder in a 84-year-old woman treated for COVID-19, according to a new ...
via Bing News